Acute Myeloid Leukemia Clinical Trials
A listing of Acute Myeloid Leukemia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Found 559 clinical trials
Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)
The investigators hypothesize that flotetuzumab for relapsed AML following allo-HCT will be safe, tolerable and may facilitate preferential immune effector cell retargeting of leukemic cells
- 0 views
- 07 Oct, 2022
- 1 location
CC-486 and Venetoclax for Acute Myeloid Leukemia
This is an open label, dose escalation Phase I single institution pilot study for relapsed and refractory AML patients using CC-486 (oral azacitidine) with venetoclax. At the completion of dose
- 0 views
- 20 Apr, 2022
- 2 locations
A Study to Evaluate MK-0482 for Relapsed/Refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML) (MK-0482-002)
a dose escalation which will follow an accelerated titration design (ATD). Part 2 is a dose expansion in the same relapsed/refractory (R/R) AML subtypes as in Part 1.
- 1 views
- 04 Oct, 2022
- 2 locations
An Open, Single Center, Randomized Controlled Clinical Study of UCB (Cord Blood) in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)
infusion after mobilization of HLA mismatched donors. Preliminary clinical studies verified that after more than 70 cases of elderly acute myeloid leukemia were treated with microtransplantation, the
- 0 views
- 22 Oct, 2022
- 1 location
Universal CAR-γδT Cell Injection in the AML Patients
To evaluate the safety of general-purpose CAR-γδT cells in patients with refractory post-transplant relapsed AML.
- 0 views
- 03 Jun, 2022
- 1 location
Dexamethasone in Refractory or First Relapsed Acute Myeloid Leukemia
regrowth and relapse. Moreover, it has been experimentally shown that leukemic cells in acute myeloid leukemia patients who relapse become sensitive to glucocorticoids treatment highlighting a novel
- 0 views
- 04 Oct, 2022
- 5 locations
Combination of Sorafenib With Standard Therapy in Newly Diagnosed Adult CBF AML
Core-binding factor acute myeloid leukemia accounts for 10-15% of AML and is categorized as favorable-risk AML. However, the 5-year CIR was up to 40% in this group of patients. Emerging data
- 0 views
- 17 Jun, 2022
- 1 location
Selinexor With Combination With Induction/Consolidation Therapy in Acute Myeloid Leukemia Patients
This pilot phase II trial studies how well selinexor works when given together with induction, consolidation, and maintenance therapy in treating older patients with acute myeloid leukemia
- 13 views
- 05 Jun, 2022
- 1 location
A Phase 1B, Open-label, Global, Multicenter, Dose Determination Study to Evaluate Safety, Tolerability, and Preliminary Efficacy of CC-486 (ONUREG®) in Combination Therapy in Subjects With Acute Myeloid Leukemia (AML) (OMNIVERSE)
The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-486 (ONUREG®) in combination with venetoclax in relapsed and/or refractory Acute Myeloid
- 0 views
- 15 Oct, 2022
- 9 locations
Phase 1/2 Study of Liposomal Annamycin in Combination With Cytarabine for the Treatment of Subjects With Acute Myeloid Leukemia (AML) That is Refractory to or Relapsed After Induction Therapy
This is a Phase 1/2, multicenter, open-label, dose-escalation study that will determine the MTD and RP2D of L-Annamycin in combination with cytarabine for the treatment of subjects with AML that
- 0 views
- 22 Oct, 2022
- 1 location